Welcome to our dedicated page for Bluejay Diagnostics news (Ticker: BJDX), a resource for investors and traders seeking the latest updates and insights on Bluejay Diagnostics stock.
Bluejay Diagnostics develops rapid, near-patient diagnostic testing for critical care settings through its Symphony™ platform. The company’s lead product candidate, the Symphony™ IL-6 Test, is designed to measure interleukin-6 for sepsis triage, patient monitoring, and risk assessment, with sample-to-result testing described at approximately 20 minutes.
Bluejay news commonly covers SYMON clinical studies, IL-6 biomarker data, conference presentations, manufacturing readiness for Symphony cartridges, antibody production for test components, and regulatory preparation. Company updates also include financing activity, warrant exercises, reverse stock splits, and other capitalization matters. The Symphony System does not yet have U.S. FDA regulatory clearance and requires authorization before it can be marketed as a diagnostic product in the United States.
Bluejay Diagnostics (NASDAQ: BJDX) announced a 1-for-4 reverse stock split effective at 12:01 a.m. ET on January 29, 2026. At the effective time every four issued and outstanding shares will be combined into one share, reducing outstanding common stock from approximately 2,834,133 shares to approximately 708,533. The company’s trading symbol BJDX remains unchanged and a new CUSIP 095633608 will be used post-split. Prefunded warrants will be adjusted from 1,055,000 to 263,750. No fractional shares will be issued; holders will receive a cash payment in lieu of fractional shares. Transfer agent Continental Stock Transfer & Trust Company will act as exchange agent and certificate holders will receive instructions. Equity awards and warrants will be proportionally adjusted.
The company noted it does not yet have FDA clearance for its Symphony System; its IL-6 sepsis test is designed for ~20-minute sample-to-result performance.
Bluejay Diagnostics (NASDAQ: BJDX) announced completion of commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6) for its Symphony™ cartridge program on December 29, 2025. The company said both antibody types met internal performance criteria for reactivity and intended diagnostic use based on internal testing.
Bluejay reported production using third-party and proprietary immunogens, plans to use its proprietary immunogen for ongoing development and IP strategy, and estimates current inventory can support production of more than nine million Symphony cartridges, with capability to produce additional antibodies as needed. Symphony remains under development and subject to further validation and regulatory review.
Bluejay Diagnostics (NASDAQ:BJDX) reported Q3 2025 results and highlighted clinical and financing progress.
Key facts: SYMON-II pivotal trial is ~50% enrolled and aims to validate IL-6 predictive performance for 28-day mortality; Symphony sample testing is planned by late 2026 and a potential FDA 510(k) submission is targeted in 2027, subject to financing. The company completed a $4.5M PIPE in October and a $3.85M warrant-inducement in April; cash was $3.08M and stockholders’ equity $3.69M as of Sept 30, 2025. Bluejay amended supply agreements with SanyoSeiko and says Symphony delivers results in ~20 minutes.
Bluejay Diagnostics (NASDAQ: BJDX) announced on October 10, 2025 the closing of a private placement that generated $4.5 million gross proceeds. The offering comprised 2,250,000 shares of common stock (or pre-funded warrants) and accompanying Series F warrants to purchase up to 4,500,000 shares at a purchase price of $2.00 per share and Series F warrant exercise price of $1.75. Series F warrants are exercisable immediately and expire in five and one-half years. Rodman and Renshaw acted as placement agent. The company said net proceeds will fund FDA approval efforts and related clinical studies, R&D, and general working capital. Securities were sold in a Regulation D/private placement with agreed resale registration rights.
Bluejay Diagnostics (NASDAQ: BJDX) announced a private placement to raise approximately $4.5 million by selling 2,250,000 shares (or pre-funded warrants) and Series F warrants to purchase up to 4,500,000 shares at a $2.00 purchase price and accompanying warrants. The Series F warrants carry a $1.75 exercise price, are exercisable immediately and expire 5.5 years after issuance. The offering is priced at-the-market under Nasdaq rules, is expected to close on or about October 10, 2025, and is being placed exclusively by Rodman and Renshaw. Net proceeds are intended to fund FDA approval efforts (including clinical studies), R&D, and general working capital. Securities will be issued under applicable exemptions and subject to resale registration rights.
Bluejay Diagnostics (NASDAQ: BJDX) and SanyoSeiko agreed on Oct. 9, 2025 to amend their Master Service Agreement and Master Supply Agreement to expand SanyoSeiko’s role in commercializing the Symphony near-patient testing platform.
Under statements of work already provided, SanyoSeiko will provide end-to-end support including manufacturing redevelopment for analyzers and cartridges, hardware/software/design updates, raw material sourcing, vendor compliance, kit assembly, labeling, packaging, shipping, quality control, regulatory and quality management support, and equipment storage and maintenance. The companies say the amended agreements aim to strengthen supply chain resilience, secure production capacity, and advance readiness for broader clinical validation and market introduction.
Bluejay Diagnostics (NASDAQ: BJDX) has reported its Q2 2025 business update, highlighting progress in its Symphony IL-6 test program. The company has initiated the SYMON-II pivotal clinical trial to validate findings from the successful SYMON-I pilot study, with completion expected by end of 2026 and FDA 510(k) submission targeted for 2027.
Key developments include a manufacturing partnership with SanyoSeiko Co. for the Symphony analyzer and an amended agreement with Toray Industries extending cartridge manufacturing timeline to October 2026. The company raised $3.85 million through warrant inducement financing in April 2025 but anticipates requiring additional capital through 2027 for manufacturing, clinical trials, and regulatory activities.
Bluejay Diagnostics (NASDAQ: BJDX) has announced the acceptance of an abstract for presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting in Philadelphia. The presentation will showcase new clinical data from the SYMON-I study, which evaluated the Symphony IL-6 Test in sepsis patients.
The study assessed IL-6 as a prognostic indicator for 28-day mortality, 7-day mortality, and microbiological positivity in patients intended or admitted to intensive care units. Dr. Nathan Shapiro from Beth Israel Deaconess Medical Center highlighted that early IL-6 testing shows promise in predicting short-term and mid-term mortality in sepsis patients.
The company is currently conducting the SYMON-II validation clinical study to further establish IL-6 as a prognostic biomarker. The presentation, titled 'Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study (SYMON I)', will be delivered by Dr. John H. Lee and Dr. Nathan Shapiro on May 14, 2025.
Bluejay Diagnostics (NASDAQ: BJDX) has announced a warrant inducement transaction that will generate approximately $3.7 million in gross proceeds. The agreement involves institutional investors who are existing warrant holders exercising their rights to purchase up to 1,085,106 shares of common stock at a reduced exercise price of $3.42 per share.
In exchange for exercising their existing warrants, investors will receive new warrants to purchase an additional 1,085,106 shares of common stock. These new warrants are immediately exercisable at $3.42 per share and will expire in five years. The transaction was facilitated by Aegis Capital Corp. as the exclusive financial advisor, with legal counsel provided by Hogan Lovells US LLP for Bluejay and Kaufman & Canoles, P.C. for Aegis.